Molecularly targeted agents in development are ushering in the age of personalized medicine. There is pressing need for better diagnostic, theragnostic, prognostic, pharmacogenomic and disease monitoring methodologies for patient selection and optimized treatment.
The source, mechanisms of action, and preclinical and clinical status,
including interim and final trial results, of all of these agents are
described in detail in New Medicine's Oncology KnowledgeBASE (nm/OK). By
interrogating nm/OK users may:
-- Identify novel agents addressing either a single target or multiple
pathways/targets and review in detail their preclinical and clinical
-- Locate targeted agents in clinical trials in combination with specific
approved cytotoxic agents or classes of such drugs, i.e. platinum-based
agents, taxanes, etc.
-- Obtain comprehensive, cited data on over 1,000 targets that may be
applicable as diagnostic, theragnostic, prognostic, pharmacogenomic,
disease monitoring and/or therapeutic targets in cancer
-- Obtain interim and final results of combination trials of approved
anticancer agents, by cancer indication, target, clinical development
-- Obtain detailed records of anticancer targets by 100 different cancer
indications, and many subtypes such as non-small cell lung cancer
(nsclc), triple receptor-negative breast cancer, glioblastoma
multiforme (GBM), etc.
-- View detailed records of drugs in development for several hundred
highly specific clinical indications, i.e. advanced or metastatic
disease, adjuvant or neoadjuvant treatment,
|SOURCE New Medicine's Oncology KnowledgeBASE|
Copyright©2007 PR Newswire.
All rights reserved